Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Strange ETMM has 170,000 on the bid at @28 and also has 170,000 on the ask @.25
There is a 170,000 shares on the bid @.28
Alexza Reports 2011 First Quarter Financial Results and Provides Business Update
Alexza (NASDAQ:ALXA)
Intraday Stock Chart
Today : Monday 9 May 2011
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the fiscal quarter ended March 31, 2011, and provided a business update. The net loss for the quarters ended March 31, 2011 and 2010, as reported in accordance with accounting principles generally accepted in the United States, was $8.4 million and $13.4 million, respectively. At March 31, 2011, Alexza had consolidated cash, cash equivalents and marketable securities of $31.8 million. Subsequent to the end of the first quarter, the Company completed a Type-C meeting with the FDA regarding a draft Risk Evaluation and Mitigation Strategy (REMS) program for AZ-004 and completed a registered direct offering with net proceeds of approximately $15.8 million.
"The start of 2011 has been highly productive for Alexza. The primary emphasis has been our continued work in preparing the AZ-004 NDA for re-submission to the FDA and the AZ-004 MAA for submission to the EMA," said Thomas B. King, President and CEO of Alexza. "As outlined previously and based on additional guidance received from the FDA, we believe the issues raised in the AZ-004 Complete Response Letter are resolvable and we remain on track to re-file the AZ-004 NDA in late July this year."
King continued, "In early March, we were approached by investors with the strategic view of strengthening our balance sheet and extending our operating runway. Our recent capital raise provides Alexza with the operational flexibility to continue our AZ-004 partnering discussions and operate the Company beyond what we believe will be the timing of our new AZ-004 PDUFA date early next year."
Alexza Business Update
The following key events, listed in chronological order, occurred since the beginning of the first quarter of 2011:
•
In January 2011, Alexza received the FDA minutes from the End-of-Review meeting with the FDA for the AZ-004 NDA in December 2010. Based on the guidance received at the End-of-Review meeting, the Company believes the issues raised in the Complete Response Letter (CRL) are resolvable and Alexza anticipates resubmitting its AZ-004 NDA in July 2011.
•
On February 22, 2011, the Company completed a voluntary employee stock option exchange program to permit the Company's eligible employees to exchange some or all of their outstanding options to purchase the Company's common stock for a lesser number of new stock options with a new vesting period. Stock options to purchase an aggregate of 2,128,430 shares of the Company's common stock, with exercise prices ranging from $2.38 to $11.70, were exchanged for stock option to purchase an aggregate of 808,896 shares of the Company's common stock with an exercise price of $1.23 per share.
•
Alexza announced that the British Journal of Psychiatry, a publication of the Royal College of Psychiatrists, in its January 2011 edition (198:51-58), published the results of the pivotal Phase 3 study evaluating AZ-004 (inhaled or Staccato loxapine) for the rapid treatment of agitation in patients with schizophrenia.
•
In April 2011, Alexza completed a Type C meeting with the FDA. The primary purpose of this meeting was to discuss preliminary draft labeling and initial REMS program proposals. The FDA granted this meeting at the Company's request, as a follow-on activity to discussions during Alexza's End-of-Review meeting held in December 2010. In the information package submitted to the FDA in preparation for this guidance meeting, Alexza included updated draft labeling and a medication guide, and initial proposals for an AZ-004 REMS program, including a draft communication plan and draft post-approval study outline.
Following the REMS guidance meeting in April 2011, Alexza believes there is agreement with the FDA on the definition of the potentially "at-risk" patient population. Additionally, Alexza and the FDA discussed key elements of screening for these "at-risk" patients, noting that no screen is 100% effective, and components to post-dosing risk mitigation in the event an "at-risk" patient receives a dose of AZ-004. The FDA emphasized that there are two key components for a risk mitigation proposal: i) adequacy of monitoring, via patient observation, for a period of time relative to the likely occurrence of a respiratory adverse reaction, and ii) availability of rescue medication (e.g., inhaled albuterol) should an adverse reaction occur.
Alexza will address this updated guidance from the FDA in its draft REMS proposal contained within the AZ-004 NDA resubmission. The FDA indicated that a complete review of the proposed REMS in conjunction with the full clinical review of the resubmitted NDA will be necessary to determine whether the REMS will be acceptable. The FDA stated it would present the AZ-004 application to an Advisory Committee. The objective of this Advisory Committee meeting would be to discuss the proposed approach for managing the risks of AZ-004 in relationship to its patient benefits.
Alexza notes that it has not received the official FDA meeting minutes from the REMS guidance meeting. The summaries in this release may be altered or supplemented by the information contained in the official meeting minutes. The Company will provide further U.S. regulatory updates on AZ-004 after receipt of the official FDA minutes or other correspondence if there are material developments in such minutes or correspondence.
•
Alexza previously received notice that AZ-004 is eligible for submission of a Marketing Authorization Application (MAA) under the centralized registration procedure with the European Medicines Agency (EMA) and was also notified of the Rapporteur and co-Rapporteur appointments for the AZ-004 review. The Company has confirmed a filing target date with the EMA and plans to submit the MAA late in the third quarter of 2011.
•
On May 6, 2011, the Company issued an aggregate of 11,927,034 shares of its common stock and warrants to purchase up to an additional 4,174,457 shares of its common stock in a registered direct offering. Net proceeds from the offering were approximately $15.8 million, after deducting estimated offering expenses. The warrants will be exercisable six months after issuance at $1.755 per share and will expire five years from the date of issuance. The shares of common stock and warrants are immediately separable and will be issued separately. The securities were sold pursuant to a shelf registration statement declared effective by the SEC on May 20, 2010.
Alexza believes that, based on its cash, cash equivalents and marketable securities balance at March 31, 2011, the net proceeds from the May financing, and the Company's expected cash usage, it has sufficient capital resources to meet its anticipated cash needs into the first quarter of 2012. Changing circumstances may cause Alexza to consume capital significantly faster or slower than currently anticipated, or to alter its operations.
Financial Results - Periods Ended March 31, 2011 and 2010
Alexza recorded $1.3 million of revenues in the quarter ended March 31, 2011, and no revenues in the quarter ended March 31, 2010. The 2011 revenues are a result payments received under the license agreement with Cypress Biosciences, Inc.
Operating expenses were $9.1 million and $12.6 million in the quarters ended March 31, 2011 and 2010, respectively. Research and development expenses were $6.3 million and $7.6 million in the quarters ended March 31, 2011 and 2010, respectively. General and administrative expenses were $2.8 million and $5.1 million in the quarters ended March 31, 2011 and 2010, respectively. Expenses in 2010 included a one-time, non-cash charge of $1.1 million related to Alexza entering into a sublease agreement for a portion of one of its Mountain View facilities.
In connection with the acquisition of Symphony Allegro, Inc. in August 2009, Alexza is obligated to pay the former Symphony Allegro stockholders certain percentages of cash payments that may be generated from collaboration transactions for AZ-004, AZ-002 (Staccato alprazolam) or AZ-104 (Staccato loxapine, low-dose). The Company records this obligation as a contingent liability and updates the liability each quarter. Alexza did not record a non-operating gain or loss during the first quarter of 2011 as compared to a non-operating loss of $0.7 million in the quarter ended March 31, 2010. Gains and losses incurred reflect Alexza's change in the estimated probability-weighted cash flows from AZ-004 and the estimated timing of receipt of such cash flows.
Conference Call Information
To access the conference call via the Web, please go to the Investor Relations tab at www.alexza.com. Please join the call at least 15 minutes prior to the start of the call to ensure time for any software downloads that may be required. Interested parties may also pre-register to avoid pre-call delays at https://www.theconferencingservice.com/prereg/key.process?key=PVNFWTCCE. A replay of the call will be available for two weeks following the event.
To access the live conference call via phone, dial 888-713-4214. International callers may access the live call by dialing 617-213-4866. The reference number to enter the call is 57197688.
The replay of the conference call may be accessed via the Web, at www.alexza.com, or via phone at 888-286-8010 for domestic callers or 617-801-6888 for international callers. The reference number for the replay of the call is 13602576.
Thanks for the update chevy
Grubb & Ellis Healthcare REIT II Expands Credit Facility With Bank of America to $45 Million
Date : 05/05/2011 @ 5:50PM
Source : PR Newswire
Stock : Grubb & Ellis (GBE)
Quote : 0.7 0.0 (0.00%) @ 7:06AM
Grubb & Ellis Healthcare REIT II Expands Credit Facility With Bank of America to $45 Million
Grubb & Ellis (NYSE:GBE)
Intraday Stock Chart
Today : Friday 6 May 2011
Grubb & Ellis Healthcare REIT II, Inc. today announced that it has modified its existing secured revolving credit facility with Bank of America, National Association. Under terms of the modification, the credit available under the facility expands to $45 million from $25 million. The credit facility may be utilized to fund property acquisitions and for other general corporate purposes.
"The continued support we're receiving from Bank of America speaks volumes about Grubb & Ellis Healthcare REIT II and the quality of the management team and product we provide to our investors," said Jeff Hanson, chairman and chief executive officer.
The credit facility matures on July 19, 2012, but may be extended at the option of Grubb & Ellis Healthcare REIT II for an additional year upon meeting certain conditions. The modified credit facility eliminates a previous all-in interest rate floor of 5 percent and bears interest at a rate equal to LIBOR plus 3.50 percent, down from 3.75 percent.
"Since beginning property acquisitions in March 2010, we have built one of the best performing portfolios among non-traded REITs," said Danny Prosky, president and chief operating officer. "Our expanded credit line with Bank of America will enable more rapid growth and further strengthen the REIT on behalf of our shareowners."
As of April 22, 2011, Grubb & Ellis Healthcare REIT II has sold approximately 23,120,666 shares of its common stock, excluding the shares issued under it distribution reinvestment plan, for approximately $230,681,000 through its initial public offering, which began at the end of the third quarter of 2009.
Grubb & Ellis Healthcare REIT II offers a monthly distribution of 6.5 percent per annum and has made 19 geographically diverse acquisitions comprised of 33 buildings valued at approximately $262 million, based on purchase price in the aggregate.
PostRock Announces First Quarter Earnings Call
Date : 05/05/2011 @ 4:34PM
Source : GlobeNewswire Inc.
Stock : PostRock Energy Corporation (PSTR)
Quote : 6.92 0.0 (0.00%) @ 7:22AM
PostRock Announces First Quarter Earnings Call
Postrock Energy Corp. (MM) (NASDAQ:PSTR)
Intraday Stock Chart
Today : Friday 6 May 2011
PostRock Energy Corporation (Nasdaq:PSTR) announced that it will host its quarterly webcast and conference call on Thursday, May 12, 2011 at 10:00 a.m. Central Time. The live webcast will be accessible on the 'Investors' page at www.pstr.com, where it will also be available for replay. The conference call number for participation is 866-516-1003.
AVI BioPharma Announces First Quarter 2011 Financial Results
Date : 05/05/2011 @ 4:00PM
Source : MarketWire
Stock : AVI BioPharma, Inc. (AVII)
Quote : 1.68 0.01 (0.60%) @ 7:22AM
AVI BioPharma Announces First Quarter 2011 Financial Results
Avi Biopharma (NASDAQ:AVII)
Intraday Stock Chart
Today : Thursday 5 May 2011
AVI BioPharma, Inc. (NASDAQ: AVII)
-- FDA Clears AVI-7100 Influenza Drug Candidate to Proceed with Phase 1
Study
-- Two New Drug Candidates Enter Phase 1 for Hemorrhagic Fever Viruses
-- Lead Duchenne Muscular Dystrophy Drug Candidate Advancing into U.S.
Placebo Controlled Trial in June
-- Continued Strong Government Contract Revenues, Over $14 Million in
First Quarter
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today reported financial results for the three months ending March 31, 2011.
"We have realized significant accomplishments this year in shaping a new vision for the company with new management and a clear strategy," said Chris Garabedian, president and chief executive officer of AVI BioPharma. "We have advanced our Duchenne muscular dystrophy clinical program, continued to execute on our government-funded infectious disease programs, and are prioritizing our early research programs for both internal development and external business partnerships."
Financial Results
For the first quarter of 2011, AVI reported an operating loss of $5.5 million, compared with an operating loss of $7.7 million in the first quarter of 2010. The reduction in the operating loss is primarily the result of a $13.1 million increase in government research contract revenues, offset by an $8.7 million increase in research and development expenses and a $2.2 million increase in general and administrative costs. The increase in the government research contract revenues and the increase in research and development costs were primarily related to the Ebola, Marburg and H1N1 government contracts that were new in 2010.
Research and development expenses were $14.8 million in the first quarter of 2011, compared to $6.1 million in the first quarter of 2010, an increase of $8.7 million. The increase was due primarily to increases in the research costs for the Ebola, Marburg and H1N1 contracts, partially offset by lower spending on the Duchenne muscular dystrophy (DMD) program and other research programs. General and administrative expenses in the first quarter were $5.0 million, compared to $2.8 million in the first quarter of 2010, an increase of $2.2 million. The increase was attributed to higher compensation costs and employee related costs resulting from the increased headcount, accrued severance and stock compensation expense associated with the expected departure of a senior officer, legal expenses, and consulting costs.
Revenue for the first quarter of 2011 increased to $14.3 million from $1.2 million in the first quarter of 2010, an increase of $13.1 million, as a result of a net increase in revenue from the Ebola, Marburg and H1N1 government research contracts.
Net income for the first quarter of 2011 was $1.8 million, or $0.02 per share, compared to a net loss for the first quarter of 2010 of $0.6 million, or $0.01 per share. The $2.4 million increase in net income was primarily due to the reduced operating loss caused by higher revenue from the new Ebola, Marburg and H1N1 contracts and the change in the valuation of certain warrants described below.
In connection with prior equity financings, AVI issued warrants that are classified as liabilities and are adjusted to fair value on a quarterly basis impacting net income (loss). The amount of the warrant liability is primarily affected by changes in AVI's stock price during each financial reporting period which causes the warrant liability to fluctuate as the market price of AVI's stock fluctuates. In the first quarter of 2011, the warrant valuation decreased by $7.3 million compared to a decrease in the warrant valuation of $7.1 million in the first quarter of 2010.
AVI had cash and cash equivalents of $23.3 million as of March 31, 2011, a decrease of $10.3 million from December 31, 2010. This decrease was due primarily to the $10.1 million of cash used in operations during the first quarter of 2011 and cash used for property and equipment and patent-related costs of approximately $0.3 million, and was partially offset by cash inflows from the exercise of warrants of $0.1 million. Accounts receivable increased $10.4 million to $13.6 million and accounts payable also increased $5.2 million to $6.5 million, both of these increases are the result of the increase in revenue from the Ebola, Marburg and H1N1 contracts.
In April 2011, AVI sold 23.0 million shares of its common stock at the price of $1.50 per share in an offering registered under the Securities Act. The offering generated gross proceeds of $34.5 million.
2011 Recent Corporate Developments
Duchenne Muscular Dystrophy (DMD) Program
-- Presented complete data from a Phase 1b/2 study of eteplirsen in DMD patients, as well as comparison of clinical and preclinical pharmacokinetic parameters of eteplirsen, at the 63rd Annual Meeting of the American Academy of Neurology.
-- Published data from two new papers in the International Journal of Toxicology demonstrating that the exon-skipping DMD drug candidate eteplirsen was well tolerated in mice and monkeys at doses up to the maximum feasible doses of 960 and 320 mg/kg, respectively. No dose limiting toxicities were seen in either species. Further, a mechanistic toxicity evaluation revealed that no toxicity was associated with exon-skipping and the resulting dystrophin expression in a dystrophic animal, the mdx mouse.
-- Received approval from the United States Adopted Names (USAN) Council of the nonproprietary name eteplirsen for AVI-4658, AVI's lead exon-skipping therapy for the treatment of DMD.
Infectious Disease Programs
-- Received notice from the U.S. Food and Drug Administration that the clinical hold on AVI-7100, AVI's lead influenza drug candidate, was removed and that AVI may proceed with its Phase 1 study.
-- Initiated Phase 1 clinical studies of AVI-6002 and AVI-6003, lead drug candidates for the treatment of Ebola virus and Marburg virus, respectively, in healthy volunteers. These studies are the first to evaluate the safety and tolerability of AVI's proprietary PMOplus™ chemistry in humans.
Corporate Developments
-- Completed public offering of common stock generating $34.5 million in gross proceeds to be used for general corporate purposes, including research and product development.
-- Appointed Peter Linsley, Ph.D., an experienced scientist widely recognized for his groundbreaking RNA-focused research and work advancing scientific discoveries into clinical development, as senior vice president and chief scientific officer.
2011 Guidance
For 2011, AVI confirms its previously provided guidance for revenue of approximately $50 million to $60 million and cash expenditures for operations, net of government funding and other collaborative efforts, to be approximately $23 million to $28 million. AVI believes it will continue to receive funding from government contracts and has assumed certain revenues from these awards in providing this guidance. If AVI does not continue to receive the funding from its current contracts, its guidance may change.
Conference Call
AVI will hold a financial results and corporate update conference call today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). The conference call may be accessed by dialing 800.215.2410 for domestic callers and 617.597.5410 for international callers. The passcode for the call is 63971514 and please specify to the operator that you would like to join the "AVI BioPharma first quarter 2011 earnings call." The conference call will be webcast live under the events section of AVI's website at www.avibio.com, and will be archived there following the call for 90 days. Please connect to AVI's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. Applying pioneering technologies developed and optimized by AVI, the Company is able to target a broad range of diseases and disorders through distinct RNA-based mechanisms of action. Unlike other RNA-based approaches, AVI's technologies can be used to directly target both messenger RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either down-regulate (inhibit) or up-regulate (promote) the expression of targeted genes or proteins. By leveraging its highly differentiated technology platform, AVI has built a pipeline of potentially transformative therapeutic agents, including a clinical stage Duchenne muscular dystrophy candidate and anti-infective candidates for influenza and hemorrhagic fever viruses. For more information, visit www.avibio.com.
Forward-Looking Statements and Information
In order to provide AVI's investors with an understanding of its current results and future prospects, this press release contains statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements about the development of AVI's product candidates, including the initiation of a Phase 2 study in June 2011 for eteplirsen, AVI's estimates regarding its future revenues and expenses and expectations regarding future success, revenues and funding from government and other sources.
These forward-looking statements involve risks and uncertainties, many of which are beyond AVI's control. Known risk factors include, among others: clinical trials may not demonstrate safety and efficacy of any of AVI's drug candidates and/or its antisense-based technology platform; development of any of AVI's drug candidates, including AVI-6002, AVI-6003 or AVI-7100, may not result in funding from the TMT in the anticipated amounts or on a timely basis, if at all; and any of AVI's drug candidates may fail in development, may not receive required regulatory approvals, or be delayed to a point where they do not become commercially viable.
Any of the foregoing risks could materially and adversely affect AVI's business, results of operations and the trading price of its common stock. For a detailed description of risks and uncertainties AVI faces, you are encouraged to review the official corporate documents filed with the Securities and Exchange Commission. AVI does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.
AVI BIOPHARMA, INC.
(A Development-Stage Company)
(in thousands, except per share amounts)
(unaudited)
Three Months Ended
March 31,
------------------
2011 2010
-------- --------
Revenues, from grants and research contracts $ 14,296 $ 1,205
Operating expenses:
Research and development 14,801 6,096
General and administrative 5,026 2,844
-------- --------
Operating loss (5,531) (7,735)
Other income (loss):
Interest income, and other net 90 42
Decrease on warrant valuation 7,274 7,109
-------- --------
Net income (loss) $ 1,833 $ (584)
======== ========
Net income (loss) per share -- basic $ 0.02 $ (0.01)
======== ========
Net income (loss) per share -- diluted $ 0.02 $ (0.01)
======== ========
Shares used in per share calculations -- basic 112,482 110,429
======== ========
Shares used in per share calculations -- diluted 121,285 110,429
======== ========
BALANCE SHEET HIGHLIGHTS
(unaudited)
(in thousands)
March 31, December 31,
2011 2010
------------ -----------
Cash and cash equivalents $ 23,283 $ 33,589
Total current assets 38,495 37,838
Total assets 47,031 45,976
Total current liabilities 43,220 45,857
Total shareholders' equity (deficit) $ 920 $ (2,817)
AVI Media and Investor Contact:
David A. Walsey
Senior Director, Investor Relations & Corporate Communications
425.354.5140
Email Contact
AVI Media Contact:
David Schull
Russo Partners
212.845.4271
Alphatec Spine Announces First Quarter 2011 Revenue and Financial Results
Date : 05/04/2011 @ 4:01PM
Source : GlobeNewswire Inc.
Stock : Alphatec Holdings, Inc. (ATEC)
Quote : 2.95 0.0 (0.00%) @ 7:22AM
Alphatec Spine Announces First Quarter 2011 Revenue and Financial Results
Alphatec Holdings, Inc. (MM) (NASDAQ:ATEC)
Intraday Stock Chart
Today : Wednesday 4 May 2011
Revenue of $49.7 million; 40.8% growth over Q1 2010; Pro Forma revenue growth of 6.6% over Q1 2010; 5.2% Growth on a Constant Currency basis
Adjusted EBITDA of $4.4 million
Net Loss of $1.9 million, or ($0.02) per share and Non-GAAP Net Income of $0.1 million, or $0.00 per share
Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, announced today financial results for the quarter ended March 31, 2011.
First Quarter 2011 Performance Highlights
Achieved record consolidated revenue of $49.7 million, representing 6.6% pro forma growth over first quarter 2010 and 8.0% sequential revenue growth over fourth quarter 2010.
-- US revenue of $33.9 million represented pro forma growth of 7.8% over first quarter 2010, exceeding the growth rate of the US spine market.
-- International revenue of $15.9 million reported in first quarter 2011 grew by 4.0% on a pro forma basis over first quarter 2010. Strong performance in Japan, Asia Pacific and Latin America drove international revenues.
Continued strong uptake and demand for PureGenTM, the Company's Osteoprogenitor Cell Allograft, with 400 cases completed by the end of first quarter 2011.
The SolusTM ALIF System, a zero-profile, single-action locking implant that is used in anterior lumbar interbody fusion (ALIF) procedures, received 510(k) clearance from the FDA and the Company has commenced a controlled launch in the US.
Continued Aging Spine market penetration of OsseoFix®, HeliFix®, and OsseoScrew® in Europe.
Addition of Patrick Ryan as Chief Operating Officer. Mr. Ryan joins Alphatec Spine from Abbott Vascular Devices, where he had been Vice President-North Asia since August 2010. Prior to that position, Mr. Ryan held senior positions with increasing responsibility in Operations at Abbott and Guidant Corporation.
Dirk Kuyper, the Company's President and Chief Executive Officer, stated: "We are pleased with the overall revenue performance that the company delivered in the first quarter of 2011. In the US, we have re-established revenue momentum and continue to achieve growth rates that exceed the US spine market. We achieved record revenues in Japan and strong growth in Asia Pacific and Latin America." Mr. Kuyper continued, "We have successfully positioned Alphatec Spine as a global leader within the spine market, and we continue to be laser-focused on driving our differentiated technologies in Aging Spine, MIS and Biologics to gain market share globally. We are particularly pleased with the rapid product uptake of PureGen, and the 510(k) clearance of Solus during the quarter."
First Quarter 2011 Financial Results
Consolidated revenues for the first quarter 2011 were $49.7 million, an increase of 40.8% from the $35.3 million reported for the first quarter 2010. US revenues for the first quarter 2011 were $33.9 million, an increase of 19.1% from the $28.4 million reported for the first quarter 2010. International revenues were $15.9 million for the first quarter 2011, more than double the $6.9 million reported in the first quarter 2010.
Gross profit for the first quarter 2011 was $32.0 million, an increase of $8.4 million over the first quarter 2010 of $23.6 million. First quarter 2011 gross margin of 64.3% was below the first quarter 2010 gross margin of 66.7%. The decrease in gross margin of 240 basis points is primarily due to geographic sales mix. While US gross margins improved as compared to prior year, the international gross margin fell as our sales base expanded dramatically into new markets. Total operating expenses for the first quarter 2011 were $34.3 million, an increase of $7.2 million compared to the first quarter 2010 of $27.1 million. The first quarter 2011 includes $0.6 million in restructuring expenses. There were no in-process research and development expenses for the first quarter 2011, a decrease of $0.5 million compared to IPR&D expense in the first quarter 2010 of $0.5 million.
Adjusted EBITDA was $4.4 million in the first quarter 2011, a decrease of $1.1 million compared to the $5.5 million reported for the first quarter 2010. The change in Adjusted EBITDA is primarily attributable to the gross margin contribution and incremental operating expenses associated with our expanded international operations, which were not present in the first quarter 2010.
Net loss for the first quarter 2011 was $1.9 million, or ($0.02) per share (basic and diluted), compared with a net loss of $4.7 million, or ($0.09) per share (basic and diluted) for the first quarter 2010.
Non-GAAP EPS for the first quarter 2011 was $0.00 per share (basic and diluted), compared to $0.00 per share (basic and diluted) reported for the first quarter 2010. Non-GAAP net earnings or (loss) excludes in-process research and development expenses, acquisition-related inventory step-up, amortization of intangible assets and restructuring expenses.
Cash and cash equivalents were $21.5 million at March 31, 2011. After adjusting for one-time cash outlays, operating cash flow was flat as compared to the cash position as of December 31, 2010.
2011 Financial Guidance
The Company reaffirms full year 2011 financial guidance with revenues of $195.0 million to $205.0 million, and $25.0 million to $28.0 million in annual adjusted EBITDA. The Company anticipates generating both net income and positive free cash flow in 2011.
Conference Call
Alphatec Spine will host a conference call today at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. To participate in the conference call, please visit the investor relations section of the Alphatec Spine website at www.alphatecspine.com. The dial-in numbers are (877) 556-5251 for domestic callers and (720) 545-0036 for international. A live webcast of the conference call will be available online from the investor relations section of the Alphatec Spine website at www.alphatecspine.com. The webcast will be recorded and will remain available on the investor relations section of Alphatec Spine's website for at least 30 days.
YES IT IS, THOUGHT I SEE A LITTLE MORE UPSIDE TODAY
ACADIA Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 10, 2011
Date : 05/03/2011 @ 9:00AM
Source : Business Wire
Stock : ACADIA Pharmaceuticals Inc. (ACAD)
Quote : 2.71 0.0 (0.00%) @ 7:22AM
ACADIA Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 10, 2011
Acadia (NASDAQ:ACAD)
Intraday Stock Chart
Today : Wednesday 4 May 2011
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2011 on Tuesday, May 10, 2011, after the U.S. financial markets close. ACADIA's management will host a conference call and webcast on Tuesday, May 10, 2011, at 5:00 p.m. Eastern Time to discuss ACADIA’s financial results and development programs.
The conference call may be accessed by dialing 866-825-3209 for participants in the U.S. or Canada and 617-213-8061 for international callers (reference passcode 78237908). A telephone replay of the conference call may be accessed through May 24, 2011 by dialing 888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for international callers (reference passcode 20761365). The conference call also will be webcast live on ACADIA’s website, www.acadia-pharm.com, under the investors section and will be archived there until May 24, 2011.
AVI BioPharma Initiates Clinical Studies for Two RNA-Based Therapeutic Candidates for Treatment of Ebola and Marburg Viruses
Date : 05/04/2011 @ 8:00AM
Source : MarketWire
Stock : AVI BioPharma, Inc. (AVII)
Quote : 1.72 0.0 (0.00%) @ 7:22AM
AVI BioPharma Initiates Clinical Studies for Two RNA-Based Therapeutic Candidates for Treatment of Ebola and Marburg Viruses
Avi Biopharma (NASDAQ:AVII)
Intraday Stock Chart
Today : Wednesday 4 May 2011
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today announced that it initiated dosing in two Phase 1 clinical studies for AVI-6002 and AVI-6003, its lead drug candidates being evaluated for the treatment of Ebola virus and Marburg virus, respectively. AVI is developing AVI-6002 and AVI-6003 under a competitively awarded contract for up to $291 million from the U.S. Department of Defense through the Joint Project Manager Transformational Medical Technologies (JPM-TMT) program. Both candidates utilize AVI's advanced and proprietary PMOplus™ chemistry.
"These are the first drug candidates employing our PMOplus chemistry to be evaluated in humans, and they are the first AVI programs to enter the clinic based on our prior studies supported by the JPM-TMT program," said Chris Garabedian, president and CEO of AVI BioPharma. "Additionally, we look forward to new and continued opportunities to earn further government support through JPM-TMT."
Each Phase 1 study will be randomized, double-blind, placebo-controlled and involve single escalating doses of AVI-6002 or AVI-6003 to assess the safety, tolerability and pharmacokinetics of each drug candidate in healthy adult volunteers. In each study, five volunteers will be enrolled in one of six cohorts for a total of up to 30 volunteers. The cohorts will include four volunteers who receive the therapeutic, and one who will receive a placebo.
Preclinical studies of AVI-6002 and AVI-6003 have been a collaborative effort between AVI and scientists at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), the U.S. Department of Defense's (DOD) lead medical research laboratory for biological defense. All preclinical studies were conducted at USAMRIID, which has the DOD's only Biosafety Level 4 (BSL4), or maximum containment capability, and is essential for studying the Ebola and Marburg viruses.
Data from preclinical studies published in Nature Medicine demonstrate that AVI-6002 and AVI-6003 provide post-exposure efficacy in non-human primates against Ebola and Marburg viruses, respectively. In multiple studies evaluating treatment of Ebola virus-infected primates with AVI-6002 and treatment of Marburg-infected primates with AVI-6003, USAMRIID scientists have observed up to 80% survival and 100% survival, respectively, when the viruses were inoculated at 1000 times the lethal dose within the confines of a BSL4 laboratory, compared to control groups where both viruses were universally lethal.
About Ebola and Marburg Viruses
Ebola hemorrhagic fever is a severe and often fatal disease in humans. The disease was first recognized in 1976 and is one of two members of a family of RNA viruses called Filoviridae. The disease is generally understood to be endemic to parts of Africa. Onset of illness from Ebola virus is abrupt with symptoms that include fever, headache, muscle ache, vomiting and stomach pain. Internal and external bleeding may also be observed in some patients. There are currently no treatments for Ebola virus infection beyond supportive care.
Marburg hemorrhagic fever is another severe and potentially fatal disease in humans first recognized in 1967. It is also caused by an RNA virus of the filovirus family and is understood to be endemic to Africa. Onset of the disease is often sudden, and the symptoms include fever, chills, nausea, vomiting, chest pain and diarrhea. Increasingly severe symptoms may also include massive hemorrhaging and multiple organ dysfunctions. There are currently no treatments for Marburg virus infection beyond supportive care.
About AVI's PMOplus Chemistry
PMOplus chemistry is an advanced generation of AVI's phosphorodiamidate morpholino oligomer, or PMO, technology pioneered by AVI. The PMO platform is designed to provide a stable chemistry backbone with superior drug-like characteristics for AVI's advanced RNA-based therapeutics. PMOplus chemistry includes specific molecular charges positionally inserted into the PMO's inherent charge-neutral backbone. The PMOplus modifications are intended to specifically enhance drug performance characteristics on two key parameters: targeted cell penetration and the maintenance of antiviral performance in the presence of viral mutation.
About JPM-TMT
Joint Project Manager Transformational Medical Technologies (JPM-TMT) is a U.S. Department of Defense (DOD) program created to protect the Warfighter from emerging, genetically altered and unknown biological threats. As the premier partner to DOD, other government agencies, academia, biotechnology and pharmaceutical industries, JPM-TMT delivers a cutting-edge and agile, end-to-end translational process for developing and providing novel response capabilities to protect the Warfighter from biological threats. Pursuant to Homeland Security Presidential Directives 10, 18, 21 and National Security Presidential Directive 33, JPM-TMT integrates early scientific discovery with the advanced development and acquisition capabilities of the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD).
About USAMRIID
U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. Department of Defense's Biological Defense Research Program, and plays a key role in national defense and in infectious disease research. The Institute conducts basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the Warfighter. While USAMRIID's primary mission is focused on the military, its research often has applications that benefit society as a whole. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command. For more information, visit www.usamriid.army.mil
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. Applying pioneering technologies developed and optimized by AVI, the Company is able to target a broad range of diseases and disorders through distinct RNA-based mechanisms of action. Unlike other RNA-based approaches, AVI's technologies can be used to directly target both messenger RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either down-regulate (inhibit) or up-regulate (promote) the expression of targeted genes or proteins. By leveraging a highly differentiated RNA-based technology platform, AVI has built a pipeline of potentially transformative therapeutic agents, including eteplirsen, which is in clinical development for the treatment of Duchenne muscular dystrophy.
Forward-Looking Statements and Information
This press release contains statements that are forward-looking, including statements about the development of AVI's product candidates, the efficacy, potency and utility of AVI's product candidates in the treatment of rare and infectious diseases, and AVI's expectations about new and continued funding from the government. These forward-looking statements involve risks and uncertainties, many of which are beyond AVI's control. Known risk factors include, among others: clinical trials may not demonstrate safety and efficacy of any of AVI's drug candidates; any of AVI's drug candidates may fail in development, may not receive required regulatory approvals, or be delayed to a point where they do not become commercially viable; and AVI may not qualify for additional or continued government funding in support of its product development programs. Any of the foregoing risks could materially and adversely affect AVI's business, results of operations and the trading price of its common stock. For a detailed description of risks and uncertainties AVI faces, you are encouraged to review the official corporate documents filed with the Securities and Exchange Commission. AVI does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.
AVI Media and Investor Contact:
David A. Walsey
Senior Director, Investor Relations & Corporate Communications
ya today
Standard & Poor's Announces Changes to U.S. Index
Cirrus Logic (NASDAQ:CRUS)
Intraday Stock Chart
Today : Tuesday 3 May 2011
S&P will make the following changes to S&P SmallCap 600 Index:
Select Comfort Corp. (NASD:SCSS) will replace Tollgrade Communications Inc. (NASD:TLGD) after the close of trading on Thursday, May 5. Private equity firm Golden Gate Capital is acquiring Tollgrade Communications in a deal expected to be completed on or about that date pending final approvals.
Cirrus Logic Inc. (NASD:CRUS) will replace Epicor Software Corp. (NASD:EPIC) after the close of trading on Friday, May 6. Private equity firm Apax Partners is acquiring Epicor Software in a deal expected to be completed soon, pending final conditions.
Standard & Poor's will monitor these transactions, and post any relevant updates on its website: www.standardandpoors.com.
Select Comfort develops, manufactures, markets, and distributes adjustable-firmness beds and other sleep-related accessory products. Headquartered in Minneapolis, MN, the company will be added to the S&P SmallCap 600 GICS (Global Industry Classification Standard) Homefurnishing Retail Sub-Industry index.
Cirrus Logic develops high-precision analog and mixed-signal integrated circuits. Headquartered in Austin, TX, the company will be added to the S&P SmallCap 600 GICS Semiconductors Sub-Industry index.
Following is a summary of the changes:
S&P SMALLCAP 600 INDEX – May 5, 2011
COMPANY
GICS ECONOMIC SECTOR
GICS SUB-INDUSTRY
ADDED
Select Comfort
Consumer Discretionary
Homefurnishing Retail
DELETED
Tollgrade Communications
Information Technology
Communications Equipment
S&P SMALLCAP 600 INDEX – May 6, 2011
COMPANY
GICS ECONOMIC SECTOR
GICS SUB-INDUSTRY
ADDED
Cirrus Logic
Information Technology
Semiconductors
DELETED
Epicor Software
Information Technology
Application Software
For more information about S&P Indices, please visit www.standardandpoors.com/indices.
About S&P Indices
S&P Indices, the world's leading index provider, maintains a wide variety of investable and benchmark indices to meet an array of investor needs. Over $1.25 trillion is directly indexed to Standard & Poor's family of indices, which includes the S&P 500, the world's most followed stock market index, the S&P/Case-Shiller Home Price Indices, the leading measure of U.S. home prices, the S&P Global BMI, an index with approximately 11,000 constituents, the S&P GSCI, the industry's most closely watched commodities index, and the S&P National AMT-Free Municipal Bond Index, the premier investable index for U.S. municipal bonds. For more information, please visit www.standardandpoors.com/indices.
For more information contact:David M. Blitzer, Ph.D.Managing Director & Chairman of the Index Committee(212) 438-3907
Alexza Prices $16.1 Million Registered Direct Offering
Date : 05/03/2011 @ 8:30AM
Source : PR Newswire
Stock : Alexza (ALXA)
Quote : 1.63 0.0 (0.00%) @ 7:22AM
Alexza Prices $16.1 Million Registered Direct Offering
Alexza (NASDAQ:ALXA)
Intraday Stock Chart
Today : Tuesday 3 May 2011
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA), or the Company, today announced that it has entered into a definitive agreement with three institutional investors, including RA Capital Management and Tavistock Life Sciences, to raise approximately $16.1 million in gross proceeds in a registered direct offering through the sale of common stock and warrants. The Company agreed to sell a total of 11,927,034 units, each unit consisting of (i) one share of common stock and (ii) one warrant to purchase 0.35 of a share of common stock, at a purchase price of $1.35 per unit. The warrants will be exercisable six months after issuance at $1.755 per share and will expire five years from the date of issuance. The shares of common stock and warrants are immediately separable and will be issued separately.
Alexza estimates that net proceeds from the offering will be approximately $15.8 million, after deducting estimated offering expenses. The Company intends to use the net proceeds from the sale of the securities primarily for general corporate purposes, including regulatory activity, clinical trial, research and development, general and administrative and manufacturing expenses.
The securities described above are being offered pursuant to a registration statement on Form S3 previously declared effective by the Securities and Exchange Commission on May 20, 2010. The transaction is expected to close on or about May 6, 2011, subject to customary closing conditions.
A copy of the prospectus supplement relating to the offering and the accompanying base prospectus may be obtained by contacting Alexza Pharmaceuticals, Inc., Attention: Corporate Secretary, 2091 Stierlin Court, Mountain View, California 94043, or by calling (650) 944-7000. A copy of the prospectus supplement relating to the offering and the accompanying base prospectus may also be accessed on the SEC website, http://www.sec.gov.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of Alexza nor shall there be any sale of such securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state.
Nite likes you better he dont like me (lol), I still cant get any shares
good luck bama, take care of yourself and your family, our prayers are with you guys
Very Nice day today,
AVI BioPharma Announces First Quarter 2011 Financial Results and Corporate Update Conference Call
Avi Biopharma (NASDAQ:AVII)
Intraday Stock Chart
Today : Thursday 28 April 2011
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, will report first quarter 2011 financial results after the NASDAQ Global Market closes on Thursday, May 5, 2011. Subsequently, at 5:00 p.m. Eastern time (2:00 p.m. Pacific time), Chris Garabedian, AVI's president and CEO, will host a conference call to discuss first quarter 2011 financial results and to provide a corporate update.
The conference call may be accessed by dialing 800.215.2410 for domestic callers and 617.597.5410 for international callers. The passcode for the call is 63971514 and please specify to the operator that you would like to join the "AVI BioPharma first quarter 2011 earnings call." The conference call will be webcast live under the events section of AVI's website at www.avibio.com, and will be archived there following the call for 90 days. Please connect to AVI's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
Sounds like a great report, ((( if i know what iam reading, I think ))
WTG Mrs EI :)
NI Technology Previews Earnings for Cirrus Logic, Microsoft, TriQuint Semiconductor, Xilinx, and Applied Micro Circuits
Cirrus Logic (NASDAQ:CRUS)
Intraday Stock Chart
Today : Wednesday 27 April 2011
Next Inning Technology Research (http://www.nextinning.com), an online investment newsletter focused on semiconductor and technology stocks, has updated outlooks for Cirrus Logic (Nasdaq: CRUS), Microsoft (Nasdaq: MSFT), TriQuint Semiconductor (Nasdaq: TQNT), Xilinx (Nasdaq: XLNX), and Applied Micro Circuits (Nasdaq: AMCC).
Next Inning editor Paul McWilliams has leveraged a decades-long career as a semiconductor industry insider to deliver in-depth insights and winning stock selections for his newsletter subscribers. McWilliams' Next Inning model portfolio has posted huge gains, returning more than 360% since its inception in 2002, and he has been picking more potential big winners for 2011.
Despite predictions from dozens of Wall Street analysts and tech sector research firms, McWilliams was the only one to forecast Intel's earnings report correctly, with estimates that matched the chip giant's Q1 results and Q2 guidance perfectly. Along with McWilliams' Intel forecast and his bullish calls ahead of strong earnings by Apple and Qualcomm, Next Inning subscribers have access to dozens more as McWilliams publishes in depth earnings previews and coverage throughout earnings season. There are still a number of potential tech earnings winners to be covered this quarter.
Trial subscribers will also receive McWilliams' highly acclaimed State of Tech series, offering in-depth, sector-by-sector coverage of over 65 leading tech companies. The full set of State of Tech reports will be published ahead of earnings season, offering specific guidance on which stocks he thinks investors should own and which should be avoided.
To take advantage of this offer and receive these reports for free, please visit the following link:
https://www.nextinning.com/subscribe/index.php?refer=prn1208
McWilliams covers these topics and more in his recent reports:
-- What are the primary challenges that lay ahead for Cirrus Logic? Should investors be concerned about Cirrus Logic's high concentration of business with Apple? How much upside can investors expect if things go right for Cirrus this year? Does the upside outweigh the potential downside? Does McWilliams think the production problems Cirrus announced recently will endanger the company's position at Apple?
-- Does McWilliams have bullish view of Microsoft based on Windows 7, Kinect, its newest mobile operating system and its expanded ecosystem strategy? Might an investment in Nokia be a better way to profit from Microsoft's mobile strategy than investing in Microsoft itself?
-- Should investors be concerned that TriQuint recently "backed away" from its relationship with Apple? Why is being an Apple supplier a "dual-edged sword?" Could the 2011 consensus estimate prove to "pitifully low," creating a significant profit opportunity for investors?
-- Is Xilinx likely to perform better than rival Altera, or will it continue to trail as it did throughout 2010? Given the surge in demand for programmable logic, does McWilliams think this is the year to split bets between the two sector leaders? What is McWilliams' estimated fair value range for Xilinx and how much upside does it represent?
-- Does McWilliams expect Applied Micro's upcoming earnings report to beat expectations? Are analysts being too pessimistic about Applied Micro with their full-year outlooks, setting the stage for significant potential profits for investors?
Founded in September 2002, Next Inning's model portfolio has returned 361% since its inception versus 49% for the S&P 500.
Alexza to Announce 2011 First Quarter Financial Results on Monday, May 9, 2011
Alexza (NASDAQ:ALXA)
Intraday Stock Chart
Today : Tuesday 26 April 2011
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it will report results for the quarter ended March 31, 2011, on Monday, May 9, 2011, following the close of the U.S. financial markets. The Company will host an investor conference call and live webcast to provide a company update, as well as to discuss the financial results, on Monday, May 9, at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. The conference call, live webcast and archived replay are open to all interested parties.
To access the conference call via the Web, please go to the Investor Relations tab at www.alexza.com. Please join the call at least 15 minutes prior to the start of the call to ensure time for any software downloads that may be required. Interested parties may also pre-register to avoid pre-call delays at https://www.theconferencingservice.com/prereg/key.process?key=PVNFWTCCE. A replay of the call will be available for two weeks following the event.
To access the live conference call via phone, dial 888-713-4214. International callers may access the live call by dialing 617-213-4866. The reference number to enter the call is 57197688.
The replay of the conference call may be accessed via the Web, at www.alexza.com, or via phone at 888-286-8010 for domestic callers or 617-801-6888 for international callers. The reference number for the replay of the call is 13602576.
EI how close are these stores to you? I would really like to know how the market it in the store and the location of it in the store
got to love it
Alphatec Holdings Announces Appointment of Patrick Ryan as Chief Operating Officer
Alphatec Holdings, Inc. (MM) (NASDAQ:ATEC)
Intraday Stock Chart
Today : Monday 25 April 2011
Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures, and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, today announced the appointment of Patrick Ryan as the Company's Chief Operating Officer.
Mr. Ryan joins the Company from Abbott Vascular Devices, where he has been the Vice President, North Asia since August 2010. This division of Abbott Vascular has annual revenues of $200 million. For the two years prior to his role in North Asia, he served as Abbott Vascular's Divisional Vice President for Canada and Latin America. Prior to that position, Mr. Ryan held two senior roles in Operations, specifically, Divisional Vice President, Worldwide Operations and Divisional Vice President, Operations, Cardiac Therapies. Before joining Abbott, Mr. Ryan held several positions with Guidant Corporation, including Vice President and Managing Director, Guidant Ireland. Prior to joining Guidant, Mr. Ryan served 14 years in the United States Navy, earning the rank of Commander. He received his MS in Petroleum Management from University of Kansas and his BS, from the United States Naval Academy.
Dirk Kuyper, the Company's President and Chief Executive Officer, stated, "We are extremely excited to welcome a professional of Pat Ryan's caliber to Alphatec Spine's management team. Pat's years of senior-level leadership on a global scale in the medical device industry will allow him to rapidly add value as our COO."
Do we know when earnings come out?
Still not to late
Sit Back and Enjoy The Ride, It Will Be Interesting
Alphatec Spine to Hold 1Q 2011 Financial Results Investor Call
Alphatec Holdings, Inc. (MM) (NASDAQ:ATEC)
Intraday Stock Chart
Today : Thursday 21 April 2011
Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a leading medical technology company involved in the design, development, manufacturing and marketing of products for the surgical treatment of spine disorders, with a focus on treating conditions affecting the aging spine, announced today that it will hold an investor call on Wednesday, May 4, 2011 to discuss the Company's first quarter 2011 financial results.
Alphatec Spine will host this webcast and conference call at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Wednesday, May 4, 2011. The dial-in numbers are (877) 556-5251 for domestic callers and (720) 545-0036 for international callers. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.alphatecspine.com. Participating in the call will be Dirk Kuyper, President and Chief Executive Officer, Michael O'Neill, Chief Financial Officer, and Ebun S. Garner, Esq., General Counsel.
After the live webcast, the call will remain available on Alphatec Spine's website for at least 30 days following the presentation.
For 2 days I cant get another share, I guess iam on the black list
I take it thats good????
Very interesting chevy, thanks for sharing that
Very interesting chevy, thanks for sharing that
wham bam boom
Cirrus Logic Reports Preliminary Fiscal Fourth Quarter Results
Cirrus Logic (NASDAQ:CRUS)
Intraday Stock Chart
Today : Thursday 14 April 2011
Cirrus Logic, Inc. (Nasdaq: CRUS), a leader in high-precision analog and digital signal processing components, today announced preliminary unaudited financial results for the fourth quarter and for fiscal year 2011, which ended March 26, 2011.
Revenue for the quarter is expected to be approximately $91.4 million, in line with guidance, representing a 46 percent increase over the $62.6 million in revenue for the fourth quarter of fiscal year 2010, and a 4 percent decrease from $95.6 million in the third fiscal quarter. Revenue for fiscal year 2011 is expected to be approximately $369.6 million, a 67 percent increase over $221 million fiscal year 2010 revenue.
Gross margin for the quarter is expected to be approximately 50 percent, below previously issued guidance of 54 to 56 percent. The company’s lower-than-expected gross margin for the quarter is the result of a charge of approximately $4.2 million, or $0.06 per share, based on 72.3 million diluted shares outstanding, due to a production issue with a new audio device that entered high volume production in March 2011. The company expects a smaller residual impact to gross margins in the first two quarters of FY2012 as the company works through in line inventory related to this product.
“FY2011 was an outstanding year for Cirrus Logic as revenue growth and operating profit improvements exceeded our own high expectations,” said Jason Rhode, Cirrus Logic president and CEO. “I’m pleased with the team’s success in meeting our customers’ demand despite the challenges resulting from a low-yielding product during a major production ramp in March. Design win activity remains excellent and I remain very excited about the future for Cirrus Logic.”
Total combined R&D and SG&A operating expenses are expected to be approximately $32.3 million, in line with company guidance, and include an estimated $2.6 million in share-based compensation and amortization of acquired intangible expenses.
The company also expects total cash and marketable securities to increase approximately $25 million to $215 million at the end of the March quarter.
you better ship me a can up here or two
EI = Private Investigator, just wish I was down there to help you my friend, all you do is greatly appreciated by me and iam sure everyone else here
Grubb & Ellis Company Receives Listing Standards Notice from NYSE
Date : 04/08/2011 @ 5:09PM
Source : PR Newswire
Stock : Grubb & Ellis (GBE)
Quote : 0.73 0.0 (0.00%) @ 3:50PM
Grubb & Ellis Company Receives Listing Standards Notice from NYSE
Grubb & Ellis (NYSE:GBE)
Intraday Stock Chart
Today : Friday 8 April 2011
Grubb & Ellis Company (NYSE: GBE), a leading real estate services and investment firm, today reported that on April 7, 2011, it was notified by the New York Stock Exchange that it is not currently in compliance with the NYSE's continued listing standards, which require a minimum average closing price of $1 per share over 30 consecutive trading days.
Subject to providing required notice and an ongoing assessment by the NYSE, the company is permitted up to a six-month period, from the date of the notification to cure this deficiency. During this period, Grubb & Ellis common shares will continue to be listed and traded on the NYSE, subject to its compliance with other NYSE continued listing standards, and a ".BC" indicator will be affixed to the GBE ticker symbol. As required, the company intends to notify the NYSE that it intends to cure the deficiency. The company's business operations, SEC reporting requirements and debt instruments are unaffected by the notification.
On March 21, Grubb & Ellis announced that it had engaged JMP Securities to explore strategic alternatives, including the potential sale or merger of the company. Grubb & Ellis also announced on March 30, that it had received an $18 million financing commitment from Colony Capital, LLC, in the form of a senior secured term loan facility, which gives Colony 60 days to evaluate the possibility of making a larger strategic investment.